Actively Recruiting
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
Led by Ming-Yuan Chen · Updated on 2026-01-09
346
Participants Needed
15
Research Sites
344 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to explore the efficacy and adverse events of reduced-dose radiotherapy (40.2Gy) versus conventional-dose radiotherapy (49.2Gy) to low-risk target volume for chemosensitive intermediate-stage nasopharyngeal carcinoma patients.
CONDITIONS
Official Title
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged between 18 and 75 years
- Pathologically confirmed non-keratinising nasopharyngeal carcinoma (WHO type II or III)
- Stage II nasopharyngeal carcinoma classified as T1-3N2M0 or T3N0-1M0
- Karnofsky Performance Status (KPS) score of 70 or higher
- Normal bone marrow function (WBC ≥ 4 x 10⁹/L, PLT ≥ 100 x 10⁹/L, HGB ≥ 90 g/L)
- Achieved complete or partial response after three cycles of gemcitabine plus cisplatin induction chemotherapy with immunotherapy
- Plasma EBV DNA level reduced to zero or below detection limit after induction chemotherapy
- Normal liver and kidney function (bilirubin, AST, ALT ≤ 2 times upper limit; creatinine clearance ≥ 60 mL/min or creatinine ≤ 1.5 times upper limit)
You will not qualify if you...
- Recurrent or metastatic nasopharyngeal carcinoma
- Pregnant or breastfeeding women
- History of malignant tumors except certain cured cancers (cervical, skin basal cell or squamous cell, localized prostate, or ductal carcinoma in situ)
- Previous radiotherapy or surgery (except diagnostic) to local lesions or lesions with necrosis unsuitable for radiotherapy
- Severe medical conditions that increase risk or affect compliance (unstable cardiac disease, renal/hepatic disease, uncontrolled diabetes, severe psychiatric disorders, other malignancies)
- History of severe allergic reactions to PD-1 monoclonal antibodies
- Allergic reactions to chemotherapy drugs used in the study (gemcitabine, docetaxel, paclitaxel variants, cisplatin)
- Need for long-term immunosuppressive therapy or corticosteroids with immunosuppressive effects
- Active tuberculosis or treatment for tuberculosis within the past year
- Other conditions making the patient ineligible as judged by the treating physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
Actively Recruiting
2
Fujian Cancer Hospital
Fuzhou, Fujian, China
Actively Recruiting
3
Sun Yat-sen University cancer center
Guangzhou, Guangdong, China
Actively Recruiting
4
the Affiliated Cancer Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Actively Recruiting
5
Cancer Hospital of Shantou University Medical College
Shantou, Guangdong, China
Actively Recruiting
6
Zhongshan City People's Hospital
Zhongshan, Guangdong, China
Actively Recruiting
7
The Fifth Affiliated Hospital of Sun Yat-sen University
Zhuhai, Guangdong, China
Actively Recruiting
8
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
Actively Recruiting
9
Wuzhou Red Cross Hospital
Wuzhou, Guangxi, China
Actively Recruiting
10
Central South University Cancer Hospital,
Changsha, Hunan, China
Actively Recruiting
11
Xiangya Hospital of Central South University
Changsha, Hunan, China
Actively Recruiting
12
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Actively Recruiting
13
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Actively Recruiting
14
Yunnan Cancer Hospital
Kunming, Yunnan, China
Actively Recruiting
15
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Actively Recruiting
Research Team
M
Ming-Yuan Chen, MD,PhD
CONTACT
R
Rui You, MD,PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here